

EXHIBIT 37


Food and Drug Administration Office of Regulatory Affairs

Collection Report

For Sample Number: 467746

This is an accurate reproduction of the original electronic record as of 04/02/2008

Payment Amount	Payment Method	704(d) Sample	702(b) Portion	Collector's Name
\$0.00	No Charge	No	No	Lillian C Lopez
Name of Signer		Date & Time of Signature		Meaning
Lillian C Lopez		03/24/2008	04:10 PM	ET
				Collector



Food and Drug Administration Office of Regulatory Affairs

Summary Report

For Sample Number: 462746

TD Sample Number:

Import Sample Number

This is an accurate reproduction of the original electronic record as of 09/23/2008

Sample Class: Normal Everyday Sample
Survey SampleSample Origin: Domestic
Sample Type: OfficialSample Basis: Surveillance
Collecting District: SAN-DO
Collection PACs: 56008A

Home District:

Orig C/R and Records To: SAN-DO

Product Name: Digoxin (Cardiotonic); Human - Rx/Single Ingredient; Delayed Release Tablets

Product Description: Digoxin Tablets, 125 mcg, RX, single ingredient

Collection Reason: FY 2008 Low Cost Generic Drug Sample Survey 2008-800 (CP 7356.008). Analyze for Uniformity of Dosage Units; Dissolution; Identification

Lab: NRL	Split Num 0	Date Received: 03/26/2008	Date Out of Lab: 09/23/2008
District:		District Conclusion	District
Conclusion:		Made By:	
Disposition Reason:		Disposition Authorized By:	Disposition Authorized Date

Performing Org	PAC	LID	PAF	Compliance No	Lab Class-Description	Laboratory Status
NRL-DCB-G	56008A		DRT		1 - In Compliance	Completed

* ab Conclusion

The product meets specifications for Identification, Dissolution, and Content Uniformity.

Lab Conclusion Date Lab Conclusion Made By
09/23/2008 Mathew, Samuel K

RECEIVED

OCT 7 2008
FDA -- SJN
COMPLIANCE BRANCH

FLAG Original

ANALYST WORKSHEET		1. PRODUCT DIGITEK (DIGOXIN TABLETS,USP) 125mcg(0.125 mg)			2. SAMPLE NUMBER 462746
3. SEALS	<input checked="" type="checkbox"/> INTACT <input type="checkbox"/> NONE	4. DATE REC'D 4/3/08	5. RECEIVED FROM Elvis Leslie	6. DISTRICT OF LABORATORY NRL	

7. DESCRIPTION OF SAMPLE

One brown, paper bag officially sealed, "462746 03/25/08 Lillian C. Lopez CST", containing two product cartons identified "462746 03/21/08 LCL Sub 1 of 2" and "462746 03/21/08 LCL Sub 2 of 2", respectively. An FDA 525 is attached to the sample.

8.	<input type="checkbox"/> NOT APPLICABLE <input checked="" type="checkbox"/> NOT DETERMINED UNITS EXAMINED	DECLARE/UNIT AMOUNT FOUND % OF DECLARED	180 tablets	9. LABEL- ING	<input type="checkbox"/> 1 ORIGINAL(S) SUBMITTED <input type="checkbox"/> 1 COPIES SUBMITTED <input type="checkbox"/> NONE
----	---	---	-------------	---------------------	--

10. SUMMARY OF ANALYSIS

Container: White, rectangular, cardboard carton approximately 14.5 cm x 6.5 cm x 7 cm. Carton contains 6 intact, rectangular, foil, blister packs. Each pack is in a separate, white, plastic case and contains 30 tablets.

Labeling: Carton has a commercially-printed, rectangular, paper, stick-on label. Commercially-printed product insert is inside carton. Plastic case has a similar commercially-printed label.

Code: "Lot No.: 7P964" and "Exp. Date: 4/09" printed on the carton label and the back of each blister pack.

Product: Round, flat and bevel, solid, light-yellow tablet. Tablet is unmarked and unscored on one side. Opposite side is 1/2-scored with markings "B" and "145". Tablet is approximately 6.5 mm in diameter.

Analysis: Identification, Dissolution, and Content Uniformity.

Method: USP 30 - NF 25, p. 1943.

Results: See general continuation sheet page 2.

11. RESERVE SAMPLE

Original, brown, paper bag officially sealed "462746 9/22/08 Valentino Fiorella Analyst" containing one open and one intact product carton. Open carton is additionally identified "VF 4/3/08". Plastic case with used blister pack containing 8 tablets is identified "#462746 4/3/08 VF Sub 2 of 2". Sample returned to the sample custodian.

12.a. ANALYST SIGNATURE (Broke Seal <input checked="" type="checkbox"/>) <i>Valentino Fiorella</i>	13. WORK- SHEET CHECK	a. BY b. DATE <i>8. matthew</i> <i>9/23/08</i>
b.		
c.	14. DATE REPORTED	<i>9/23/08</i>

Sept # 462746
Back of page 1

RF 9/22/08

GENERAL CONTINUATION SHEET	PRODUCT	SAMPLE NO.
	Digoxin Tablets (0.125 mg)	462746
<p><u>RESULTS:</u></p> <p><u>Identification</u></p> <p>The retention time of the major peak in the chromatogram of the <i>sample preparation</i> corresponds to that in the chromatogram of the <i>standard preparation</i>. <u>Complies</u></p> <p><u>Content Uniformity</u> (See computer printout pages 6 - 7 for complete results)</p> <p>Range: <u>97.1 %</u> to <u>102.1 %</u>; Average (\bar{x}): <u>99.4 %</u>; RSD: <u>1.8 %</u>; s: <u>1.74</u></p> <p>Acceptance Value (AV) = <u>4.2 %</u></p> <p>(Limit: AV ≤ 15.0 % unless otherwise specified in the individual monograph)</p> <p><u>Dissolution</u> (See least squares line fitting pages 11 - 12 for complete results)</p> <p>Range: <u>93.4 %</u> to <u>111.6 %</u>; Avg.: <u>105.0 %</u></p> <p>(Limit: Each unit is NLT Q+5% (Q=80%) for 6 units tested (Stage 1))</p>		
ANALYST(S)	<u>Valentino Acrielle</u>	
ANALYST NO.	113	PAGE 2 OF 12 PAGES

SPL# 462746
Back of Page 2
5/20/08
VF

DIGOXIN TABLETS
(USP 30-NF 25, p.1943)

Reference Std:

USP Digoxin RS # 1200000-05, Lot 00B096, dried in vacuum at 105°C for 1 hour prior to use. For quantitative applications, use a value of 0.961 mg of digoxin per mg on the dried basis.

Reagents: Fisher Scientific Acetonitrile, Lot 073938 (Rec'd 11/1/07)
Sigma Digoxigenin, Lot No. 016K3777 (Rec'd 2/6/08)

Filter: PALL Life Sciences Acrodisc 25 mm Syringe Filter with 0.45 μ m Nylon Membrane, Lot A10529577

Identification

The retention time of the major peak in the chromatogram of the sample preparation corresponds to that in the chromatogram of the standard preparation. Complies

Content Uniformity

Mobile Phase: Water/Acetonitrile (74/26)

System Suitability Solution

(Balance: Cahn C-31 Microbalance, FDA No. 5004472 - QA by G. Lehr on 1/14/08)

4.025 mg USP Digoxin RS + 4.122 mg Digoxigenin
----> 100.0 ml Diluted Alcohol

Standard Solution 1 (CCV)

(Balance: Cahn C-31 Microbalance, FDA No. 5004472 - QA by G. Lehr on 1/14/08)

2.522 mg USP Digoxin RS ----> 100.0 ml Diluted Alcohol
25.0 ml
-----> 50.0 ml Diluted Alcohol

Standard Solution 2 (ICV/Check Std.)

(Balance: Cahn C-31 Microbalance, FDA No. 5004472 - QA by G. Lehr on 1/14/08)

2.505 mg USP Digoxin RS ----> 100.0 ml Diluted Alcohol
25.0 ml
-----> 50.0 ml Diluted Alcohol

GENERAL CONTINUATION SHEET	PRODUCT	SAMPLE NO.
	Digoxin Tablets (0.125 mg)	462746
ANALYST(S)	ANALYST NO.	PAGE 3 OF 12 PAGES
<i>Valentino Fiorella</i>	113	

SPL# 462746
 Back of Page 3
 5/20/08
 v/f

Content Uniformity

Sample Solution

For each of 10 tablets tested:

1 tablet (0.125 mg) ----> 10.0 ml Diluted Alcohol ----> Filter

Chromatographic System

(See pp. 2 - 3 , Attachment A for chromatograms)

Resolution (R)

$$R = \frac{2(t_2 - t_1)}{w_1 + w_2} = \underline{20.7} \quad [\text{Limit: } R \text{ is NLT 4.0}]$$

Theoretical Plates (N)

$$N = 16(t/w)^2 = \underline{5315} \quad [\text{Limit: } N \text{ is NLT 1200}]$$

Tailing Factor (T)

$$T = [W_{0.05}/2f] = \underline{1.1} \quad [\text{Limit: } T \text{ is NMT 2.0}]$$

Relative Std. Deviation (RSD)

(See computer calculation, page 5)

$$RSD = \underline{0.18\%} \quad [\text{Limit: } RSD \text{ is NMT 2.0\%}]$$

Standard 2 Calculation (ICV/Check Std.)

(See pp. 3 - 8 , Attachment A for chromatograms)

$$\% \text{ Digoxin} = \frac{\text{Area Std.2}}{\text{Area Std.1}} \times \frac{\text{Std 1 Wt.}}{\text{Std 1 Dilution}} \times \frac{\text{Std 2 Dilution}}{\text{Std 2 Wt.}} \times 100$$

Area Std.1 = Avg. area of 5 std. injections. (See computer calculation, p. 5)
 Std.Wt.1 = (2.522 mg) (0.961) = 2.424 mg
 Std.Wt.2 = (2.505 mg) (0.961) = 2.407 mg

$$\% \text{ Digoxin} = \frac{675184}{678145} \times \frac{2.424 \text{ mg}}{200.0 \text{ ml}} \times \frac{200.0 \text{ ml}}{2.407 \text{ mg}} \times 100 = \underline{100.3\%}$$

GENERAL CONTINUATION SHEET	PRODUCT	SAMPLE NO.
	Digoxin Tablets (0.125 mg)	462746
ANALYST(S)	ANALYST NO.	PAGE <i>4</i> OF <i>62</i> PAGES
<i>Valentino Fiorella</i>	113	

SPL# 462746
Back of Page 4
5/21/08
VF

Standard 1 Calculation (CCV)

(See pp. 3 - 7 and page 27, Attachment A for chromatograms)

$$\% \text{ Digoxin} = \frac{\text{Area Std.1(9)}}{\text{Area Std.1}} \times \frac{\text{Std 1 Wt.}}{\text{Std 1 Dilution}} \times \frac{\text{Std 1 Dilution}}{\text{Std 1 Wt.}} \times 100$$

Area Std.1 = Avg. area of 5 std. injections. (See computer calculation, p. 5)

Area Std.1(9) = Area of Std.1, Injection 9. (See page 27, Attachment A)

Std.Wt.1 = (2.522 mg) (0.961) = 2.424 mg

$$\% \text{ Digoxin} = \frac{679031}{678145} \times \frac{2.424 \text{ mg}}{200.0 \text{ ml}} \times \frac{200.0 \text{ ml}}{2.424 \text{ mg}} \times 100 = \underline{100.1\%}$$

Calculations

(See computer printout pages 6 - 7 for complete results and pages 9 - 13, Attachment A for chromatograms)

+22-26 ^{Sample}
Area Std.1 = Avg. area of 5 std. injections. (See computer calculation, p. 5)
Std.Wt.1 = (2.522 mg) (0.961) = 2.424 mg

If $98.5\% \leq X \leq 101.5\%$, then $M = X$

Range: 97.1% to 102.1%; Average(X): 99.4%; RSD: 1.8%; s: 1.74

Acceptance Value(AV) = $M - X + ks$

$$AV = (2.4) (1.74) = \underline{4.18\%}$$

(Limit: AV $\leq 15.0\%$ unless otherwise specified in the individual monograph)

General Continuation Sheet	Product: Digoxin Tablets (0.125 mg)	Sample No. 462746
-------------------------------	-------------------------------------	-------------------

Statistical Analysis of Data: Standard Solution 1 (CCV) 05/20/2008

Relative STD Deviation	0.18 %
Standard Deviation	1202.05229
Average (mean)	678145.2
Number of entries	5
Range	676751 To 679893

Data Entered:

676751
677360
678550
678172
679893

Analyst(s) <i>Valentino Fiaile</i>	Analyst No. 113	Page 5 of 12 Pages
------------------------------------	-----------------	--------------------

General Continuation Sheet	Product: Digoxin Tablets (0.125 mg)	Sample No. 462746
----------------------------	-------------------------------------	-------------------

Content Uniformity

05/21/2008

No. of Units Examined	10
Standard Weight	2.424 mg.
Standard Dilution	200
Sample Dilution	10

Data Entered:

Unit #1	707447	STD #1	678145
Unit #2	687826	Blank	0
Unit #3	691235		
Unit #4	695615		
Unit #5	678836		
Unit #6	681037		
Unit #7	711029		
Unit #8	714211		
Unit #9	692266		
Unit #10	689421		

CONTENT UNIFORMITY RESULTS:

FOUND (mg/tablet)	DECLARED	% of DECLARED
UNIT #1 0.126	0.125 mg/tablet	101.1
UNIT #2 0.123		98.3
UNIT #3 0.124		98.8
UNIT #4 0.124		99.5
UNIT #5 0.121		97.1
UNIT #6 0.122		97.4
UNIT #7 0.127		101.7
UNIT #8 0.128		102.1
UNIT #9 0.124		99.0
UNIT #10 0.123		98.6
AVG. 0.124		99.4

OFFICIAL LIMITS:	90.0	%	TO	105.0	%
No. of Units Examined	10				
RANGE	97.1	%	TO	102.1	% of Declared
UNITS >=85 BUT <=115 % of Avg. Limit	:				10
UNITS >=75 BUT <85 OR >115 BUT <=125 % of Avg. Limit	:				0
UNITS <75 OR >125 % of Avg. Limit	:				0
REL. STD. DEV. :	1.8	LIMIT	<= 6.0%		

mg/unit = (R_spl * std_wt * spl_dil) / (R_std * std_dil * 1 unit)

Analyst(s) <i>Valentino Fiorelli</i>	Analyst No. 113	Page 6 of 62 Pages
--------------------------------------	-----------------	--------------------

General Continuation Sheet	Product: Digoxin Tablets (0.125 mg)	Sample No. 462746
Statistical Analysis of Data: Content Uniformity Standard Deviation 05/21/2008		
Relative STD Deviation 1.75 %		
Standard Deviation 1.74		
Average (mean) 99.36		
Number of entries 10		
Range 97.1 To 102.1		
Data Entered:		
101.1		
98.3		
98.8		
99.5		
97.1		
97.4		
101.7		
102.1		
99		
98.6		

Analyst(s) <i>Valentino Fisicella</i>	Analyst No. 113	Page 7 of 12 Pages
---------------------------------------	-----------------	--------------------

GENERAL CONTINUATION SHEET	PRODUCT	SAMPLE NO
	Digoxin Tablets (0.125 mg)	462746
ANALYST(S)	ANALYST NO.	PAGE 8 OF 12 PAGES
<i>Valentino Farrell</i>	113	

SPL# 462746
Back of Page 8
9/15/08
VF

Dissolution

Medium: 0.1N HCl, 500 ml (37.0°C ± 0.5°C)

Apparatus 1: 120 rpm

Time: 60 minutes

Instrument: Distek Dissolution Apparatus #1, FDA No. 1218
(QA by F.Maldonado on 7/7/08)

Instrument: Shimadzu Fluorescence Spectrophotometer, FDA# 5004459
(QA by V.Fiorella on 7/1/08)

Reagents: Sigma L-Ascorbic Acid, Lot 10K0256 (Rec'd before 4/10/06)

Sigma-Aldrich 30% H₂O₂, Batch# 04824AH (Rec'd 4/3/08)

Fisher Scientific Methanol, Lot 081717 (Rec'd 5/27/08)

Fisher Scientific HCl, Lot 068102 (Rec'd 5/4/07)

Filter: PALL Life Sciences Acrodisc Premium 25 mm Syringe Filter with
0.45 um GHP Membrane, Lot 21688684

Ascorbic acid-Methanol Solution

(Mettler Toledo AX205, FDA No. 5099471 - QA by D.Dai on 7/10/08)

201.9 mg Ascorbic acid ----> 100.0 ml MeOH

Hydrogen peroxide-Methanol Solution

Stock Solution: 2.0 ml 30% H₂O₂ ----> 100.0 ml MeOH (Refrigerate)

Working Solution: 2.0 ml Stock ----> 100.0 ml MeOH

Standard Solutions

(Mettler Toledo AX205, FDA No. 5099471 - QA by D.Dai on 7/10/08)

Stock Solution

25.09 mg USP Digoxin RS ----> 500.0 ml Dilute Alcohol (4 in 5)

10.0 ml

-----> 100.0 ml Dilute Alcohol (4 in 5) [0.005 mg/ml]

GENERAL CONTINUATION SHEET	PRODUCT Digoxin Tablets (0.125 mg)	SAMPLE NO. 462746
ANALYST(S) <i>Valentino Scirella</i>	ANALYST NO. 113	PAGE 9 OF 12 PAGES

SPL# 462746
 Back of Page 9
 9/16/08
 VF

Working Standard Solutions

Standard Solution	ml Stock Solution	ml Dissolution Medium	Final Concentration (mg/ml)
20%	1.0	100.0	0.00005
40%	2.0	100.0	0.00010
60%	3.0	100.0	0.00015
80%	4.0	100.0	0.00020
100%	5.0	100.0	0.00025

Test Solution (6 tablets tested; 0.125 mg/tablet)

1 tablet ---> 0.1N HCl, 500 ml ---> Filter [0.00025 mg/ml]

Procedure

Test Prep.: 1.0 ml Test Solution (*Prepared in duplicate*)
 + 1.0 ml Ascorbic acid-Methanol Solution
 + 5.0 ml HCl
 + 1.0 ml Hydrogen peroxide-Methanol Solution
 ----> Glass-stoppered flask

Std. Preps.: 1.0 ml of each Working Std. Solution
 + 1.0 ml Ascorbic acid-Methanol Solution
 + 5.0 ml HCl
 + 1.0 ml Hydrogen peroxide-Methanol Solution
 ----> Glass-stoppered flask

Blank Prep.: 1.0 ml Dissolution Medium
 + 1.0 ml Ascorbic acid-Methanol Solution
 + 5.0 ml HCl
 + 1.0 ml Hydrogen peroxide-Methanol Solution
 ----> Glass-stoppered flask

Procedure

After 2 hours (FDA Timer# 1678 - QA by A.Vargas on 1/18/08), measure the fluorescence of each preparation at an emission wavelength of about 485 nm and an excitation wavelength of about 372 nm correcting each reading for the blank.

Plot a standard curve of Fluorescence vs. % Dissolution.

Determine the % dissolution of digoxin for each Test Solution from the graph.

GENERAL CONTINUATION SHEET	PRODUCT Digoxin Tablets (0.125 mg)	SAMPLE NO. 462746
ANALYST(S) <i>Valentino Scicchitano</i>	ANALYST NO. 113	PAGE 10 OF 12 PAGES

General Continuation Sheet	Product: Digoxin Tablets (0.125 mg)	Sample No. 462746
----------------------------	-------------------------------------	----------------------

Least Squares Line Fitting

09/17/2008

The Line Fitting used is $Y = mX + b$
 with $m = 0.02381$
 and $b = -0.0498$
 Correlation Coefficient = 0.999204448

Data Entered:

	X	Y	LSLF y	% Deviation
20% Std.	20	0.452	0.4264	6.004
40% Std.	40	0.874	0.9026	3.169
60% Std.	60	1.352	1.3788	1.944
80% Std.	80	1.892	1.855	1.995
100% Std.	100	2.324	2.3312	0.309

Extrapolated Data:

	X	Y
Tablet 1-Test 1	93.86	2.1850
Tablet 1-Test 2	92.94	2.1630
Tablet 2-Test 1	104.19	2.4310
Tablet 2-Test 2	101.04	2.356
Tablet 3-Test 1	110.45	2.58
Tablet 3-Test 2	110.07	2.571

Analyst(s)	Valentina Facciella	Analyst No. 113	Page 11 of 12 Pages
------------	---------------------	--------------------	---------------------

SPL# 462746
 Back of Page 10
 8/17/08
 VF

Results

See least squares line fitting calculation, pages 11 - 12, and Attachment B for spectra.

<u>Name</u>	<u>EM @ 485 nm</u>	<u>Corrected EM @ 485 nm</u>
Blank	-0.008	0
20% Std. Solution	0.444	0.452
40% Std. Solution	0.866	0.874
60% Std. Solution	1.344	1.352
80% Std. Solution	1.884	1.892
100% Std. Solution	2.316	2.324
Tablet 1-Test 1	2.177	2.185
Tablet 1-Test 2	2.155	2.163
Tablet 2-Test 1	2.423	2.431
Tablet 2-Test 2	2.348	2.356
Tablet 3-Test 1	2.572	2.58
Tablet 3-Test 2	2.563	2.571
Tablet 4-Test 1	2.582	2.59
Tablet 4-Test 2	2.617	2.625
Tablet 5-Test 1	2.56	2.568
Tablet 5-Test 2	2.559	2.567
Tablet 6-Test 1	2.401	2.409
Tablet 6-Test 2	2.344	2.352
100% Std. Solution	2.379	2.387

<u>Tablet</u>	<u>% Dissolution 1</u>	<u>% Dissolution 2</u>	<u>Avg. % Dissolution</u>
1	93.86	92.94	93.40
2	104.19	101.04	102.62
3	110.45	110.07	110.26
4	110.87	112.34	111.61
5	109.95	109.9	109.93
6	103.27	100.87	102.07
AVG			104.98

[Limit: Each unit is NLT Q + 5% (Q=80%) for 6 units tested (Stage 1)]

General Continuation Sheet	Product: Digoxin Tablets (0.125 mg)	Sample No. 462746
----------------------------	-------------------------------------	----------------------

Least Squares Line Fitting

09/17/2008

The Line Fitting used is $Y = mX + b$
 with $m = 0.02381$
 and $b = -0.0498$
 Correlation Coefficient = 0.999204448

Data Entered:

	X	Y	LSLF y	% Deviation
20% Std.	20	0.452	0.4264	6.004
40% Std.	40	0.874	0.9026	3.169
60% Std.	60	1.352	1.3788	1.944
80% Std.	80	1.892	1.855	1.995
100% Std.	100	2.324	2.3312	0.309

Extrapolated Data:

	X	Y
Tablet 4-Test 1	110.87	2.5900
Tablet 4-Test 2	112.34	2.6250
Tablet 5-Test 1	109.95	2.5680
Tablet 5-Test 2	109.90	2.567
Tablet 6-Test 1	103.27	2.409
Tablet 6-Test 2	100.87	2.352

Analyst(s)

*Valentino Gielle*Analyst No.
113

Page 12 of 12 Pages